

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03271554 ML30132

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Alectinib was approved by the Ministry of Food and Drug Safety (MFDS) in Korea in Oct 2016. The purpose of this registry is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and effectiveness of the new drug so that the regulatory authority can manage the marketing approval properly.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03271554 ML30132
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 19 Years

Healthy Volunteers
No
